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Abstract
Objective: Weight reduction improves several obesity-related health conditions. We aimed to compare
the effect of bariatric surgery and comprehensive lifestyle intervention on type 2 diabetes and obesity-
related cardiovascular risk factors.
Design: One-year controlled clinical trial (ClinicalTrials.gov identiﬁer NCT00273104).
Methods: Morbidly obese subjects (19–66 years, mean (S.D.) body mass index 45.1 kg/m
2 (5.6), 103
women) were treated with either Roux-en-Y gastric bypass surgery (nZ80) or intensive lifestyle
intervention at a rehabilitation centre (nZ66). The dropout rate within both groups was 5%.
Results: Among the 76 completers in the surgery group and the 63 completers in the lifestyle group,
mean (S.D.) 1-year weight loss was 30% (8) and 8% (9) respectively. Beneﬁcial effects on glucose
metabolism, blood pressure, lipids and low-grade inﬂammation were observed in both groups.
Remission rates of type 2 diabetes and hypertension were signiﬁcantly higher in the surgery group
than the lifestyle intervention group; 70 vs 33%, PZ0.027, and 49 vs 23%, PZ0.016.
The improvements in glycaemic control and blood pressure were mediated by weight reduction.
The surgery group experienced a signiﬁcantly greater reduction in the prevalence of metabolic
syndrome, albuminuria and electrocardiographic left ventricular hypertrophy than the lifestyle group.
Gastrointestinal symptoms and symptomatic postprandial hypoglycaemia developed more frequently
after gastric bypass surgery than after lifestyle intervention. There were no deaths.
Conclusions: Type 2 diabetes and obesity-related cardiovascular risk factors were improved after both
treatment strategies. However, the improvements were greatest in those patients treated with gastric
bypass surgery.
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Introduction
Obesity (body mass index (BMI) R30 kg/m
2) and its
metabolic consequences, hyperglycaemia and high
blood pressure, are major risk factors of cardiovascular
morbidity and mortality (1, 2). Alongside tobacco usage
and physical inactivity they represent the ﬁve leading
global risks to mortality (3). In addition, several
other cardiovascular risk factors, such as metabolic
syndrome, albuminuria, left ventricular hypertrophy
and low-grade inﬂammation, are all closely associated
with obesity (4–7).
As the prevalence of obesity, and especially extreme
obesity, has dramatically increased in the last few
decades (8), so too has the usage of bariatric surgery
to treat morbid obesity (BMIR40 kg/m
2 or BMI
R35 kg/m
2 with at least one obesity-related comorbid-
ity) (9). Currently, the most commonly performed
bariatric procedure worldwide is the Roux-en-Y gastric
bypass surgery (9). Several studies have documented
how obesity surgery allows for large weight reduction
and improvements in obesity-related conditions
(10–15). Furthermore, comprehensive lifestyle inter-
vention programmes have also demonstrated, although
to a lesser extent, signiﬁcant short-term weight
reduction and improvements in cardiovascular risk
factors in moderate to severely obese subjects (16–19).
Importantly, increased physical activity, a pivotal
component of all lifestyle intervention programmes,
has been shown to have positive metabolic effects
beyond weight reduction (20). However, only two
controlled clinical trials have compared the effect of
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resolution of diabetes and cardiovascular risk factors
(10, 11). In these studies, the average weight loss in
the non-surgically treated groups was negligible. Not
all morbidly obese subjects are suitable for bariatric
surgery and therefore non-surgical treatment alter-
natives are needed.
The objective of this 1-year non-randomised
controlled clinical trial was to compare the effect of
Roux-en-Y gastric bypass surgery and a comprehensive
lifestyle intervention programme on type 2 diabetes and
obesity-related cardiovascular risk factors.
Subjects and methods
Study design and participants
This study was conducted at a public tertiary care
centre at Vestfold Hospital Trust, Tønsberg, Norway.
Although preferable when conducting a clinical trial,
we did not ﬁnd randomisation to be appropriate.
According to Norwegian guidelines, treatment seeking
morbidly obese subjects should be offered either
conservative or surgical therapy (21). We therefore
considered it unethical to assign patients to surgery if
they qualiﬁed for a lifestyle intervention programme
and preferred this course of treatment to surgery.
This stance also held vice versa.
In order to participate in the non-randomised
controlled morbid obesity treatment, bariatric surgery
versus intensive lifestyle intervention (MOBIL) study
consecutive patients were pre-screened between
December 2005 and May 2006 (Fig. 1). The MOBIL
study aimed to address changes in several health
outcomes related to obesity. Clinical and laboratory
examinations were performed during pre-screening.
Furthermore, patients who satisﬁed the criteria for
bariatric surgery (22) and wanted either gastric bypass
surgery or intensive lifestyle intervention were referred
to a screening examination which included an oral
glucose tolerance test, a somnography, pulmonary
function tests, quality of life questionnaires and a
structured dietary interview. All patients underwent a
thorough assessment conducted by a multidisciplinary
team consisting of an internist, a dietician and, in cases
of surgery, a surgeon before treatment. These health
professionals provided complete information about the
possible risks and beneﬁts of an operation and
encouraged patients to incorporate their own values
and preferences into the decision-making process. Each
patient and their physician agreed together upon the
most appropriate choice of therapy. The elapsed period
of time between the pre-screening examination and
the screening examination was 18 weeks (11); this did
not differ signiﬁcantly between the study groups
(PZ0.063). By contrast, the time between the
screening examination and either the date of surgery
or the start of lifestyle intervention was signiﬁcantly
longer in the surgery group than in the lifestyle group,
65 weeks (14) versus 19 weeks (15) (P!0.001).
One-year follow-up was completed by June 2009. This
article reports changes in weight, glucose- and lipid
metabolisms, blood pressure, albuminuria, left ventri-
cular hypertrophy, low-grade inﬂammation, energy
intake and physical activity.
The study was approved by the regional ethics
committee of what was formerly known as the Southern
Norway Regional Health Authority. The study is
registered in the ClinicalTrials.gov-registry under the
unique trial number NCT00273104. Written informed
consent was provided by all the participants.
Intervention
Both treatment groups were seen by an internist half
yearly and by a dietician when required. Changes in
medicationsweremadeonanindividualbasisbyboththe
patients’ general practitioner and by hospital physicians.
Patients in the surgical group completed a low-calorie
diet (3.3–3.8 MJ/day) in 3–6 weeks preceding surgery.
A Roux-en-Y gastric bypass surgery was performed
laparoscopically in 74 of the 76 surgically treated
patients. The gastric pouch was about 25 ml, while
the intestinal limb lengths were measured as follows:
alimentary limb, median 120 (range 80–250) cm;
biliopancreatic limb, median 100 (range 50–170) cm;
and common channel, variable length. The bariatric
Pre-screened (n=228)
Screened (n=181)
Not eligible (n=47)
Completed the
study (n=76)
Not enrolled (n=35)
-BMI<35kg/m2 (n=3)
-Previous malabsorptive surgery (n=3)
-Pregnancy (n=2)
-Withdrew (n=17)
-Postponed treatment (n=4)
-Alternative bariatric procedures (n=6)
Withdrew (n=2)
Excluded due to
pregnancy (n=2)
Completed the
study (n=63)
Withdrew (n=2)
Excluded due to
cancer (n=1)
Intensive lifestyle
intervention (n=66)
Gastric bypass
surgery (n=80)
Enrolled (n=146)
Figure 1 Flow of participants throughout the study.
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patients. After surgery, a standardised regimen of
dietary supplements (23) and a proton pump inhibitor
were prescribed to all patients. Patients with a high risk
of venous embolism were prescribed low-molecular
weight heparin. During follow-up, patients allocated to
surgery were examined by a bariatric surgeon 6 weeks
post surgery, while groups of patients were seen by a
dietician quarterly. To optimise the result of the
procedure patients were encouraged, both before and
after the surgery, to normalise their eating behaviour
and to increase their physical activity level.
The majority (59/63) of patients in the lifestyle group
were referred to a rehabilitation centre specialising in the
care of morbidly obese patients (Evjeklinikken). Using a
cognitiveapproachtheprogrammeatthiscentreaimedto
induce a weight loss of at least 10%. Each patient was
motivated to increase their physical activity and to
normalise their eating habits. The 1-year lifestyle
programme comprises four stays at the rehabilitation
centre lasting for either 1 week or 4 weeks (Fig. 2).
The daily programme was divided between organised
physical activity (3–4 h) and different psychosocially
oriented interventions. The interventions involved indi-
vidualconsultationswithamedicaldoctor,anutritionist,
a physiotherapist and a trained nurse. Those leading the
counselling interviews were trained in motivational
interviewing, a client-centred counselling style that
aims to invoke behaviour change. The patients also took
part in group sessions focusing on emotional aspects of
sedentarybehaviouraswellasclassroomlessonsontopics
related to nutrition, physical activity and co-morbidities.
No special diet or weight-loss drugs were prescribed,
but patients were encouraged to follow the guidelines of
the Norwegian National Council ofNutrition (24), which
recommend that the daily intake of protein, fat,
carbohydrate and alcohol should account respectively
for 10–20, !30, 50–60 and !5% of energy consumed.
Outside of these stays, patients were contacted by phone
onceevery2weeks.Theywereencouragedtoself-monitor
their eating habits and physical activities, as well as to
visit their general practitioner for a consultation and
weight control check once every 4 weeks. The remaining
four participants were allocated to two rehabilitation
centreswithcomparableinterventionprogrammes.Fifty-
four patients (86%) attended all scheduled centre visits.
Outcome variables
Demographic and clinical data were recorded on
standardised forms. Height, weight and waist and hip
circumferences were measured with patients in an
upright position wearing light clothing and no shoes.
A 75 g oral glucose tolerance test was performed at
0800 h after an overnight fast. Type 2 diabetes was
diagnosed in patients who used glucose-lowering agents
or had fasting serum glucose R7.0 mmol/l and/or 2 h
serumglucoseR11.1 mmol/l(25).Remissionofdiabetes
was deﬁned as either partial (serum glucose levels
below the diagnostic cut-off values and HbA1c !6.5%)
or complete (fasting serum glucose !5.6 mmol/l, 2 h
glucose!7.8 mmol/landHbA1c!6.2%)intheabsence
of glucose-lowering agents (26). Combined remission
rates (partial and complete) are presented unless
otherwise speciﬁed.
Blood pressure was measured three times after at
least 5 min rest. The average of the second and third
measurements was registered. Patients using anti-
hypertensive drugs, as well as those with systolic
blood pressure R140 mmHg and/or diastolic blood
pressure R90 mmHg (27) were categorised as having
hypertension. Remission of hypertension was deﬁned
as blood pressure below the diagnostic cut-off values in
the absence of anti-hypertensive drugs.
Metabolic syndrome was deﬁned according to the
modiﬁed ATP III criteria (28). Albuminuria was deﬁned
as present if the albumin to creatinine ratio was
R2.5 mg/mmol in men and R3.5 mg/mmol in
women (29). The product of QRS complex duration
times Cornell voltage combination (RaVLCSV3, with
6 mm added in women) was used with a thresholdvalue
of 2440 mm!ms to identify electrocardiographic left
ventricular hypertrophy (30). Regression of electro-
cardiographic left ventricular hypertrophy estimated
by the Cornell voltage-duration product is known to
predict regression of echocardiographic left ventricular
hypertrophy (31).
Dietary intake and physical activity during the
preceding year were assessed through structured
interviews performed by registered dieticians. Data
were recorded on an optically readable food frequency
questionnaire (Department of Nutrition, University of
Oslo, Norway). Similar questionnaires have been
validated using weighted records (32). Questionnaire
data were scanned using Teleform 10.0 (Cambridge,
UK). Dietary intake was calculated using a data-
base assembled from ofﬁcial food composition tables
(Norwegian Nutrition Council, 1995). Calculations
were computer driven (Kostberegningssystem 6.0;
University of Oslo, Norway). Time spent performing
light (e.g. casual walking), moderate (e.g. brisk
walking) and vigorous (e.g. jogging) intensity aerobic
physical activities in periods of 10 min or more was
recorded. Participants who performed 150 min or
more per week of moderately intense aerobic physical
activities were considered to be physically active, as
1 week
Rehabilitation
center
4 weeks
Rehabilitation
center
1 week
Rehabilitation
center
1 week
Rehabilitation
center
10 weeks
Home
23 weeks
Home
12 weeks
Home Figure 2 Schedule of stays during the
1-year lifestyle programme at Evjeklinikken.
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more per week of vigorously intense aerobic physical
activities (33).
Perioperative (ﬁrst 30 days) and late (after 30 days)
complicationswererecordedineachpatient’srecordﬁle.
In addition, all medical emergencies, hospitalisations
and gastrointestinal side effects were reported on
standardised self-report questionnaires. Reported symp-
tomatic postprandial hypoglycaemia was documented
by blood glucose !2.8 mmol/l (34). Complications and
medical emergencies not recorded in each patient’s
record ﬁle at our hospital were veriﬁed by reports from
other institutions.
Laboratory analyses
Blood samples were collected either in the fasting state
or during the oral glucose tolerance test. Samples
clotted 30 min at room temperature, and serum was
separated bycentrifugation. Analyses of blood lipids and
glucose were performed by dry reagent slide technology
on the Vitros 950 Analyzer until November 2006 and
the Vitros FS 5.1 Analyzer (Ortho-Clinical Diagnostics,
New York, NY, USA) thereafter. HbA1c was analysed
using HPLC on Tosoh HLC-723 G7 (Tosoh Corporation,
Tokyo, Japan).
Serum samples collected during the oral glucose
tolerance test were either stored at K80 8C or analysed
on the day of collection (glucose). Insulin, C-reactive
protein and adiponectin were measured in stored serum
obtained before the glucose ingestion. Insulin was
analysed using an RIA (Millipore Corporation, Billerica,
MA, USA), whereas C-reactive protein and adiponectin
were analysed using enzyme immunoassays (R&D
systems, Minneapolis, MN, USA). All samples were
measured in duplicate. The intra- and inter-assay
coefﬁcients of variation were !10% for all assays.
Albumin and creatinine in urine were analysed using
Konelab 60i (Thermo Electron Corporation, Helsinki,
Finland) until August 2008 and Vitros FS 5.1
Chemistry System thereafter.
Statistical analysis
The sample size of the MOBIL study was calculated
(80% statistical power, a-level of 0.05 and equal
distribution to the treatment groups) based on antici-
pated remission rates of type 2 diabetes and obstructive
sleep apnoea. Given remission rates of type 2 diabetes of
70% in the surgery group and 20% in the lifestyle
group, at least 30 subjects with type 2 diabetes were
required. Expecting a prevalence of type 2 diabetes of
25% and a dropout rate of 30% from the screening
examinations, a minimum of 172 subjects were
required for screening.
Data are presented as mean (S.D.) or number (%)
unless otherwise speciﬁed. Skewed data were trans-
formed using natural logarithms to approximate
normality. Between-group comparisons at baseline
were analysed using independent samples t-test or
Mann–Whitney U test for continuous variables and c
2
or Fisher’s exact test for categorical variables. Within-
group comparisons were performed using paired
samples t-test or repeated measures ANOVA for
continuous variables and McNemar test for dichoto-
mised variables. Between-group changes in outcome
variables were assessed using logistic and linear
regression analyses, analysis of covariance, repeated
measures ANOVA and Fisher’s exact test. Furthermore,
changes in categorical and continuous variables were
adjusted for baseline differences. In addition, continu-
ous variables were, in the entire study population,
adjusted for gender, age, BMI at baseline and changes in
relevant medication. Regression analyses were used to
identify predictors of remission of diabetes and
hypertension and to explore the independent effects of
several variables on changes in HbA1c and blood
pressure. For each variable, only subjects who had
values available at both baseline and follow-up are
presented and included in the analyses. There were
!5% missing and/or excluded data unless otherwise
noted. The signiﬁcance level was P!0.05. Statistical
analyses were performed using SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Baseline characteristics of participants
Patient ﬂow throughout the study is shown in Fig. 1.
Of the 146 patients included, 80 chose to have surgery
and 66 chose to participate in a lifestyle intervention
programme. The completion rate was 95%. Baseline
characteristics of the participants who completed the
study are shown in Table 1. No signiﬁcant differences
were found between the two study groups in terms
of sex, ethnicity, obesity-related comorbidities or the
usage of weight-loss drugs or statins. However, patients
who chose gastric bypass surgery were on average
4 years younger and 12 kg heavier than those in the
lifestyle group.
Weight reduction
Weight changes in the two treatment groups during the
study are shown in Fig. 3A. Mean (S.D.) percentage
1-year weight reduction was 30% (8) in the surgery
group and 8% (9) in the lifestyle group (within-groups
both P!0.001 and between-groups P!0.001). This
corresponds to a mean (S.D.) loss of excess weight above
25 kg/m
2 of 67% (18) and 20% (23) (P!0.001)
respectively.
The cumulative distribution of percentage weight
change in the two treatment groups is shown in Fig. 3B.
Within the lifestyle group, 62% lost R5% of their initial
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Within the surgery group, all subjects experienced a
weight reduction O10% of their initial weight.
Changes in measures of obesity, glucose
metabolism, blood pressure, lipids and
inﬂammatory markers
With the exception of pulse pressure, changes in
anthropometric measures, blood pressures and bio-
chemical risk factors were signiﬁcantly greater in the
surgery group than in the intensive lifestyle group
(Table 2). Both treatment groups experienced a
signiﬁcant reduction in all measures of obesity, glucose
metabolism, blood pressure, total and low-density
lipoprotein cholesterol, triglycerides and C-reactive
protein during follow-up (all P%0.034). Adiponectin
increased signiﬁcantly in both treatment groups (both
P!0.001), whereas high-density lipoprotein choles-
terol increased signiﬁcantly only in the surgery group
(P!0.001).
Subgroup analyses including subjects with R10%
weight reduction showed that multi-adjusted (gender,
age, BMI, baseline value and change in relevant
medications) between-group changes in HbA1c and
systolic and diastolic blood pressures did not differ
signiﬁcantly between the surgically and the conserva-
tively treated groups (mean (95% CI) 0.0 (K0.2 to 0.2)
%, PZ0.965; K2( K7 to 4) mmHg, PZ0.536; and K3
(K7 to 1) mmHg, PZ0.115, respectively).
Regression analyses, including percentage weight
change, treatment choice, gender, age, BMI, baseline
value and change in relevant medication as indepen-
dent variables, showed that weight loss, but not
treatment choice, was signiﬁcantly associated with
reduction in HbA1c and systolic blood pressure, but
not diastolic blood pressure (R
2Z0.712, bZ0.206,
PZ0.008; R
2Z0.580, bZ0.313, PZ0.001; and
R
2Z0.423, bZ0.140, PZ0.210).
Table 1 Participant characteristics at baseline. Data are given as
mean (S.D. ) ,m e d i a n( r a n g e ) ,o rn (%). Differences between
categorical data were determined using either c
2 or Fisher’s exact
test, whilst independent sample t-test or Mann–Whitney U test were
used for continuous data.
Surgery
(nZ76)
Lifestyle
(nZ63) P value
Age (years) 42.8 (10.5) 47.0 (11.0) 0.023
Gender (female) 53 (70%) 44 (70%) 0.989
Caucasian 74 (97%) 61 (97%) 0.849
Type 2 diabetes 20 (26%) 18 (29%) 0.766
Duration of type
2 diabetes (years)
1 (0 to 31) 0 (0 to 16) 0.235
Hypertension 41 (54%) 40 (64%) 0.256
Metabolic syndrome 58 (76%) 44 (70%) 0.390
Albuminuria 11 (15%)
a 7 (13%)
b 0.745
Left ventricular hypertrophy 13 (17%)
c 7 (11%)
d 0.319
Coronary heart disease 5 (7%) 4 (7%) 1.000
Weight (kg) 137 (21) 125 (20) 0.001
Body mass index (kg/m
2) 46.7 (5.7) 43.3 (5.0) !0.001
Waist circumference (cm) 135 (13) 129 (12) 0.009
Waist-to-hip ratio 0.99 (0.09) 0.97 (0.09) 0.447
Glucose, fasting (mmol/l) 6.8 (2.3) 6.4 (1.7) 0.520
Glucose, 2 h (mmol/l) 7.5 (3.4)
e 7.6 (3.1)
f 0.877
Insulin, fasting (pmol/l) 247 (106) 228 (111) 0.254
HbA1c (%) 5.9 (1.1) 5.7 (0.8) 0.520
Systolic BP (mmHg) 133 (18) 135 (16) 0.510
Diastolic BP (mmHg) 83 (11) 83 (10) 0.857
Pulse pressure (mmHg) 51 (13) 52 (14) 0.476
Total cholesterol (mmol/l) 5.1 (1.1) 5.2 (1.0) 0.724
LDL cholesterol (mmol/l) 3.1 (0.9) 3.3 (0.9) 0.226
HDL cholesterol (mmol/l) 1.2 (0.3) 1.2 (0.3) 0.457
Triglycerides (mmol/l) 1.8 (1.0) 1.5 (0.9) 0.013
C-reactive protein (mg/l) 2.9 (2.4) 3.2 (3.9) 0.408
Adiponectin (mg/ml) 5.7 (3.2) 5.8 (3.4) 0.721
Energy intake (MJ/day) 11.2 (4.5)
g 12.0 (3.8)
h 0.293
Physically active
i 7 (10%)
g 10 (18%)
h 0.179
Currently smoking 21 (28%) 21 (33%) 0.466
Weight loss drugs 4 (5%) 2 (3%) 0.689
Statins 10 (13%) 7 (11%) 0.798
LDL, low density lipoprotein, HDL, high density lipoprotein.
anZ72;
bnZ53;
cnZ75;
dnZ62;
enZ64;
fnZ55;
gnZ73;
hnZ55;
iR150 min of moderately intense or R60 min of vigorously intense aerobic
physical activity per week.
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baseline. In contrast, 2 (4%) patients in the lifestyle
group and 15 (23%) patients in the surgery group had
2h g l u c o s e !2.8 mmol/l after the intervention
(PZ0.003).
Type 2 diabetes and hypertension
Among participants with type 2 diabetes, HbA1c was
reduced from 6.6% (1.0) to 6.3% (0.9) in the lifestyle
group and from 7.1% (1.5) to 5.8% (0.5) in the surgery
group (adjusted between-group difference, PZ0.003).
Moreover, the hypertensive subgroups’ systolic blood
pressure declined from 144 mmHg (16) to 125 mmHg
(12) after the surgical procedure and from 143 mmHg
(15) to 130 mmHg (14) after the lifestyle intervention
(adjusted between-group differences, PZ0.061).
Furthermore, the number of diabetic subjects using
glucose-lowering agents dropped (from 11 to 6) in the
surgery group and increased (from 6 to 10) in the
lifestyle group (between-group difference, PZ0.017). In
contrast, the reduction in the number of hypertensive
participants using anti-hypertensive drugs did not differ
signiﬁcantly between the surgery group (from 24 to 21)
and the lifestyle group (from 30 to 25) (between-group
difference, PZ1.00).
The remission rates of type 2 diabetes and hyperten-
sion related to weight change after gastric bypass
surgery and lifestyle intervention are shown in Fig. 4.
The remission rates of both conditions were signiﬁcantly
higher after surgical treatment than after lifestyle
intervention. Complete remission of type 2 diabetes
was signiﬁcantly more frequent in the surgery group
than in the lifestyle group (11/14 vs 0/6, PZ0.002).
Multiple regression analyses demonstrated that no
usage of glucose-lowering agents and anti-hypertensive
drugs at baseline were, independent of percentage
weight change and treatment choice, associated with
remission of type 2 diabetes (PZ0.023) and hyperten-
sion (P!0.001). In addition, univariate linear
regression analyses showed that greater reductions in
HbA1c and systolic blood pressure were associated
with surgical treatment (bZK0.408, PZ0.011 and
bZK0.187, PZ0.096 respectively). Inclusion of
percentage weight change in the regression analyses
showed that weight loss mediated the effects of treat-
ment choice on these outcomes (bZ0.406, PZ0.160
and bZ0.142, PZ0.410 respectively). Furthermore,
weight loss was signiﬁcantly associated with reductions
in HbA1c and systolic blood pressure (bZ0.926,
PZ0.002 and bZ0.423, PZ0.016 respectively).
Metabolic syndrome, albuminuria and left
ventricular hypertrophy
The changes in the number of individuals with
metabolic syndrome (K44 vs K14), albuminuria
(K7 vs 3) and left ventricular hypertrophy (K10 vs
K2) were signiﬁcantly greater in the surgery group
than in the lifestyle group (Fig. 5). The prevalence
of metabolic syndrome reduced signiﬁcantly in
both treatment groups (both P%0.001), while the
Table 2 Changes from baseline in various continuous variables. Unadjusted within-group changes are given as mean (S.D.). Adjusted
between-group differences and corresponding P value were calculated with the use of analysis of covariance and presented as mean (95%
CI). All between-group differences were adjusted for gender, age, baseline body mass index, and baseline values. Furthermore, fasting and
2-h glucose, insulin and HbA1c were adjusted for change in the usage of glucose lowering agents; systolic and diastolic blood pressure and
pulse pressure were adjusted for change in the usage of anti-hypertensive drugs; and total cholesterol, low and high density lipoprotein
cholesterol, and triglycerides were adjusted for the change in the usage of statins.
Surgery (nZ76) Lifestyle (nZ63)
Adjusted between-group
difference, mean (95% CI) P value
Weight (kg)
a K41.3 (13.1) K10.7 (12.0) K27.6 (K31.7 to K23.5) !0.001
Body mass index (kg/m
2) K14.0 (4.1) K3.7 (4.2) K9.4 (K10.8 to K8.0) !0.001
Waist circumference (cm)
a K30.3 (10.5) K10.3 (10.6) K17.8 (K21.3 to K14.4) !0.001
Waist-to-hip ratio K0.06 (0.06) K0.01 (0.07) K0.05 (K0.07 to K0.03) !0.001
Glucose, fasting (mmol/l) K1.9 (2.0) K0.8 (1.0) K0.8 (K1.1 to K0.5) !0.001
Glucose, 2 h (mmol/l) K4.2 (3.2) K1.6 (1.9) K2.4 (K3.0 to K1.8) !0.001
Insulin, fasting (pmol/l) K142 (96) K53 (84) K77 (K100 to K54) !0.001
HbA1c (%) K0.4 (0.9) K0.1 (0.5) K0.2 (K0.3 to K0.0) 0.047
Systolic blood pressure (mmHg) K14 (16) K10 (15) K4( K8t oK0) 0.028
Diastolic blood pressure (mmHg) K12 (10) K6 (11) K5( K8t oK2) 0.002
Pulse pressure (mmHg) K2 (14) K4 (12) 1 (K3 to 4) 0.760
Total cholesterol (mmol/l) K1.2 (1.1) K0.7 (0.8) K0.4 (K0.6 to K0.2) !0.001
LDL cholesterol (mmol/l) K1.0 (0.8) K0.5 (0.7) K0.5 (K0.7 to K0.4) !0.001
HDL cholesterol (mmol/l) 0.2 (0.3) 0.0 (0.2) 0.2 (0.2 to 0.3) !0.001
Triglycerides (mmol/l) K0.9 (1.0) K0.4 (0.8) K0.2 (K0.3 to K0.0) 0.014
C-reactive protein (mg/l) K2.1 (2.2) K1.4 (3.6) K1.0 (K1.5 to K0.6) !0.001
Adiponectin (mg/ml) 3.9 (3.8) 1.8 (3.2) 2.0 (1.0 to 3.0) !0.001
Energy intake (MJ/day) K4.7 (4.5) K3.5 (3.5) K1.7 (K2.3 to K1.0) !0.001
LDL, low density lipoprotein, HDL, high density lipoprotein.
aNot adjusted for body mass index.
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ﬁcantly reduced in only the surgery group (PZ0.002).
In contrast, the prevalence of albuminuria did not
change signiﬁcantly within either treatment group.
Lifestyle and medications
Although both treatment groups reported signiﬁcantly
lower energy intake at 1 year than at baseline (both
P!0.001), the reduction was signiﬁcantly greater in
the surgery group than in the lifestyle group (Table 2).
The number of subjects in the surgery group and
lifestyle group which either moved from being inactive
to active (12 vs 18), stayed inactive or active (57 vs 32)
or moved from being active to inactive (4 vs 5) differed
signiﬁcantly between the groups (Fig. 6). Overall, there
was a greater increase in the physical activity level of
the lifestyle group than the surgery group. However, the
median (range) time spent performing physical activi-
ties with moderate or vigorous intensity after the
interventions did not differ signiﬁcantly between the
surgery and lifestyle groups, 20 (0–510 min) versus 65
(0–660 min), PZ0.148.
Usage of weight-loss medications was stopped in all
surgically treated patients and started in only one
patient in the lifestyle group. The change in the number
of individuals using statins did not differ signiﬁcantly
between the surgery and the lifestyle (10 vs 3,
PZ0.114).
Last observation carried forward
In additional calculations, missing values were replaced
by the last observed value of the respective variable
(data not shown). These results did not alter the
conclusions of the study.
Adverse events
Median (range) post-operative stay was 2 (1–9) days.
Perioperative complications in the surgery group
included one gastrojejunal anastomotic leakage,
which was successfully re-operated on during the ﬁrst
post-operative day, one major bleeding at the site of the
trocar insertion, which needed a blood transfusion, and
two pneumonias treated effectively with antibiotics.
Late complications in the surgerygroup included four
patients with symptomatic cholelithiasis (imaging
veriﬁed), two patients with marginal ulcers, ﬁve patients
with postprandial hypoglycaemia, one patient with a
fracture of the ﬁfth right proximal phalange and one
patient with myocardial infarction. In the lifestyle
group, one patient was diagnosed with breast cancer,
one patient suffered a right ankle fracture that was
treated with a stabilising cast and complicated by a deep
venous thrombosis and one patient developed chole-
lithiasis. There were no deaths.
In total, 48% (33/69) of patients in the surgerygroup
and 7% (4/59) of patients in the lifestyle group
developed gastrointestinal symptoms, including
abdominal pain, nausea, vomiting, diarrhoea and
constipation (P!0.001).
Discussion
Toourknowledge,thisistheﬁrstcontrolled,clinicaltrial
that has sought to evaluate the effects of gastric bypass
surgery and intensive lifestyle intervention on cardio-
vascular risk factors. When compared with the lifestyle
group, the surgery group had higher remission rates
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Figure 5 The prevalence of metabolic syndrome, albuminuria and
left ventricular hypertrophy in the treatment groups at both baseline
and 1-year follow-up. Between-group differences at 1 year were
adjusted for differences in prevalence at baseline using logistic
regressionanalyses. Pvaluesareforcomparisonsbetweensurgery
and lifestyle groups.
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Figure 4 Remission of type 2 diabetes and hypertension at
1 year correlated to percentage weight change in individuals
treated with gastric bypass surgery or intensive lifestyle
intervention. Red triangles represent patients treated with gastric
bypass surgery, while blue circles represent subjects who chose
lifestyle intervention. Open triangles/circles denote complete
remission of type 2 diabetes and remission of hypertension, half
ﬁlled triangles/circles denote partial remission of type 2 diabetes
and ﬁlled triangles/circles denote no remission. For deﬁnitions of
partial and complete remission of type 2 diabetes, see ‘Subjects
and methods’ section. Mean percentage weight changes
(black diamonds) within the groups are shown with bars
extending from the diamonds representing 95% CI. Odds
ratios (OR) were calculated using logistic regression analyses.
Combined (partial and complete) remission of type 2 diabetes
was used in the analysis.
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reductions in the prevalence of metabolic syndrome,
albuminuria and left ventricular hypertrophy. Notably,
intensive lifestyle intervention was also associated with
favourable changes in measures of glucose metabolism,
blood pressure, lipids and low-grade inﬂammation.
Strengths and weaknesses of the study
The strengths of this study include the prospective
design, the fact that the control group obtained a
signiﬁcant weight loss from lifestyle intervention and
the high participant completion rate. Limitations of the
study include the lack of randomisation (addressed in
‘Subjects and methods’ section), a larger intervention
delay in the surgery group and the short-term follow-
up. Furthermore, the diagnoses of type 2 diabetes and
hypertension were, in the absence of hypoglycaemic or
anti-hypertensive drugs, based on only one measure-
ment and not repeated measurements as recommended
(25, 27). Finally, the majority of the study population
was of Europoid origin, meaning that the results of
this study cannot be generalised to include other
ethnic groups.
Type 2 diabetes and hypertension
Both the case controlled Swedish Obese Subjects (SOS)
study (10) and the Australian randomised controlled
clinical trial (11) demonstrated that 2 year remission
rates of type 2 diabetes were signiﬁcantly higher in
patients treated with bariatric surgery than in con-
servatively treated controls. The SOS studyalso reported
higher remission rates of hypertension in the surgery
group. Our studyextends these ﬁndings by showingthat
morbidly obese patients treated with gastric bypass
surgery were more likely to achieve remission of type 2
diabetes and hypertension than those who participated
in a comprehensive lifestyle intervention programme.
In addition to a shorter intervention period, our study
differs from these previous trials in several ways. First, in
contrast with our standardised and comprehensive
lifestyle programme, the above two studies are notable
for the fact that non-surgical treatment varied consider-
ably and that weight loss was negligible. Second, our
surgical procedure was gastric bypass, whereas purely
restrictive, bariatric procedures were mainly imple-
mented in the two other studies. Accordingly, the
average 1-year weight reduction was more pronounced
in our surgical group. Third, our deﬁnition of remission
of type 2 diabetes differed slightly from the previous
studies. Finally, the Australian study differed in the
sense that it only included those patients who had type
2 diabetes of !2 years duration and a BMI of between
30 and 40 kg/m
2. Nevertheless, despite these
differences, the remission rate of diabetes in our surgical
group was nearly identical with rates in these previous
studies (70 vs 71 and 72%). Furthermore, while
hypertension was resolved in approximately half the
surgical patients in our study, it did so in only one-third
of the patients in the SOS study.
Our study shows that weight reduction, and not
treatment choice, predicted improvement in glycaemic
control and systolic blood pressure. Furthermore, most
of the beneﬁcial metabolic effects were observed after a
weight reduction of R10%. Accordingly, the metabolic
effect of gastric bypass surgery seems to be mediated
through weight reduction.
Despite extensive weight loss, type 2 diabetes and
hypertension in a substantial number of surgically
treated patients were not resolved. In contrast, remis-
sion of these conditions was observed in some lifestyle
group patients despite only modest weight reduction.
These ﬁndings might be explained by differences in the
severity of the conditions and the possible beneﬁcial
effect of increased physical activity. Indeed, the absence
of glucose-lowering drugs and anti-hypertensive
medication independently predicted remission of both
diabetes and hypertension. Furthermore, compared
with subjects treated with surgery, a signiﬁcantly higher
proportion of the participants in the lifestyle group
became physically active.
Bothbloodglucoseand bloodpressure are continuous
riskfactorsfordeathandcardiovasculardisease(35,36).
The observed decline in these measures in both
intervention groups may therefore have positive health
effects. Conversely, the ﬁve cases of symptomatic
postprandial hypoglycaemia and the large proportion
(23%) of patients with 2 h glucose !2.8 mmol/l in
the gastric bypass group raise some concerns. Severe
postprandial hypoglycaemia after Roux-en-Y gastric
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Figure 6 Change in physical activity during 1-year follow-up. The
proportion of participants who went from being physically active
(R150 min of moderate or R60 min of vigorous aerobic physical
activity per week) to inactive (reduced) were still physically active or
inactive(unchanged) or went frombeingphysicallyinactiveto active
(increased). The changes were adjusted for baseline activity level
using linear regression analysis. P value is for comparisons
between surgery and lifestyle groups.
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post-surgical nesidioblastosis may contribute to this
complication (37). Furthermore, severe and sympto-
matichypoglycaemiaintype2diabeticsubjectshasbeen
shown to be associated with increased mortality (38).
Consequently,itcannotbeexcludedthatthereductionin
2 h glucose observed after Roux-en-Y gastric bypass
surgery mayalso have negative long-term health effects.
Other cardiovascular risk factors
Surgical therapy was superior to lifestyle intervention
both in terms of the resolution of metabolic syndrome,
left ventricular hypertrophy and microalbuminuria, as
well as with respect to improvements in inﬂammatory
markers. In line with previous studies, we report that
weight reduction was associated with resolution of
metabolic syndrome (11, 17), beneﬁcial changes in
C-reactive protein and adiponectin levels (16) and
reduction in left ventricular mass (12). Improvement
in all renal parameters, including albuminuria, has
been reported after gastric bypass surgery (13).
Similarly, weight reduction after lifestyle intervention
has been reported to resolve albuminuria (17).I n
contrast to this ﬁnding and closer to our own results,
modest weight reduction in the intensive lifestyle group
of the Diabetes Prevention Program did not reduce
albumin excretion signiﬁcantly (39).
Clinical and research implications of the work
In sum, we have shown that gastric bypass surgery is
more effective than intensive lifestyle intervention in
terms of improving type 2 diabetes and obesity-related
cardiovascular risk factors. However, morbidly obese
patients treated with lifestyle intervention also experi-
enced signiﬁcant and meaningful improvements in most
cardiovascular risk factors, and signiﬁcantly more
patients in the lifestyle group than the surgery group
became physically active. Gastric bypass surgery was
associated with a signiﬁcantly higher risk of gastro-
intestinal symptoms and complications as reported
previously (40). Furthermore, although a speciﬁed set
of dietary supplements seems to prevent vitamin
deﬁciencies after gastric bypass surgery (23), several
deﬁciencies may occur if an inadequate supple-
mentation is prescribed (41). Finally, even though
reduced overall mortality after bariatric surgery has
been reported (42), it is still unclear whether short-term
improvement in obesity-related cardiovascular risk
factors translates into long-term reduced cardiovascular
morbidity and mortality. Our results indicate that when
treating morbidly obese patients, gastric bypass surgery
should not, despite its ability to improve risk factors,
be considered the default course of treatment. Rather,
both patient and physician should consider the possible
side effects of this treatment, and, where appropriate,
take up alternative conservative treatments. Indeed,
intensive behavioural intervention has been shown to
result in long-term weight reduction in some patients
(43), while improved physical ﬁtness is known to reduce
all cause mortality (44). Moreover, it should be
emphasised that if the success of bariatric surgery is to
be optimised then behavioural changes are also
necessary (45). Future studies comparing surgery and
non-surgical treatment programmes should address the
effect of these treatments on long-term cardiovascular
morbidity and mortality.
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